Dabigatran in real-world atrial fibrillation

Summary

In the RE-LY clinical trial, dabigatran presented a better effectiveness/ safety profile when compared to warfarin. However, clinical trials are not very representative of the real-world setting. We aimed to assess the performance of dabigatran in real-world patients with atrial fibrillation (AF) by means of a systematic review and meta-analysis of observational comparison studies with vitamin K antagonists (VKA). We searched PubMed, Embase and Scopus databases until November 2015 and selected studies according to the following criteria: observational study performed with nonvalvular AF patients; reporting adjusted hazard ratios (HR) of clinical events in a follow-up period; for dabigatran 75 mg, 110 mg or 150 mg versus VKA. Twenty studies were selected which included 711,298 patients, 210,279 of which were treated with dabigatran and the remaining 501,019 with VKA. Ischaemic stroke incidence was of 1.65 /100 patient-years for dabigatran and 2.85/100 patient-years for VKA (HR 0.86, 95 % confidence interval of 0.74–0.99). Major bleeding rate was 3.93/100 patient-years for dabigatran and 5.61/100 patient-years for VKA (0.79, 0.69–0.89). Risk of mortality (0.73, 0.61–0.87) and intracranial bleeding (0.45, 0.38–0.52) were significantly lower in patients treated with dabigatran when compared to patients on VKA. Risk of gastrointestinal (GI) bleeding was significantly higher in patients treated with dabigatran (1.13, 1.00–1.28). No significant difference was observed in risk of myocardial infarction (0.99, 0.89–1.11). In this combined analysis of real-world observational comparison studies with VKA, dabigatran was associated with a lower risk of ischaemic stroke, major bleeding, intracranial bleeding and mortality, higher risk of GI bleeding and a similar risk of myocardial infarction.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Atrial fibrillation - dabigatran - vitamin K antagonist - real-world - meta-analysis

• References

• 1 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
• 2 Hart RG, Pearce LA, Aguilar MI.. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 3 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation*. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
• 4 Connolly SJ, Ezekowitz MD, Yusuf S. et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 5 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RELY trial. N Engl J Med 2010; 363: 1875-1876.
• 6 Björklund E, Lindahl B, Stenestrand U. et al Swedish ASSENT-2; RIKS-HIA Investigators. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J 2004; 148: 566-573.
• 7 Gitt AK, Bueno H, Danchin N. et al. The role of cardiac registries in evidence-based medicine. Eur Heart J 2010; 31: 525-529.
• 8 Carmo J, Costa FM, Ferreira J, Mendes M.. Dabigatran in Real World of Atrial Fibrillation: Systematic Review and Meta-analysis of Comparison Studies With Vitamin K Antagonists. Circulation 2015; 132: A12465.
• 9 Romanelli RJ, Nolting L, Dolginsky M. et al. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2016 Epub ahead of print.
• 10 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-2012.
• 11 Hartling L, Milne A, Hamm MP. et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol 2013; 66: 982-993.
• 12 DerSimonian R, Laird N.. Meta-analysis in clinical trials. Control Clin Trials 1986; 07: 177-188.
• 13 Deeks JJ, Altman DG, Bradburn MJ.. In: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care: meta-analysis in context. 2nd ed.. London: BMJ Publication Group; 2001: 313-335.
• 14 Deeks JJ, Higgins JPT, Altman DG.. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011
• 15 Egger M, Davey SG, Schneider M. et al. Bias in meta-analysis detected by a simple graphical test. Br Med J 1997; 315: 629-634.
• 16 Ho JCS, Chang AM, Yan BP. et al. Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong. Clin Cardiol 2012; 35: 40-45.
• 17 Larsen TB, Rasmussen LH, Skjøth F. et al Efficacy and Safety of Dabigatran Et-exilate and Warfarin in ’Real-World’ Patients with Atrial Fibrillation: A Prospective Nationwide Cohort Study. J Am Coll Cardiol 2013; 61: 2264-2273.
• 18 Larsen TB, Rasmussen LH, Gorst-Rasmussen A. et al. Myocardial ischaemic events in 'real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014; 127: 329-336.
• 19 Larsen TB, Gorst-Rasmussen A, Rasmussen LH. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656.
• 20 Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E. et al Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
• 21 Graham DJ, Reichman ME, Wernecke M. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
• 22 Ho CW, Ho MH, Chan PH. et al. Ischaemic stroke and intracranial haemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
• 23 Hernandez I, Baik SH, Pinera A. et al. Risk of bleeding with dabigatran in atrial fibrillation. J Am Med Assoc Intern Med. 2015 Epub ahead of print.
• 24 Bouillon K, Bertrand M, Maura G. et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2015; 02: e150-e159.
• 25 Lauffenburger JC, Farley JF, Gehi AK. et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc 2015; 04: e001798.
• 26 Abraham NS, Singh S, Alexander GC. et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J 2015; 350: h1857.
• 27 Chang HY, Zhou M, Tang W. et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. Br Med J 2015; 350: h1585.
• 28 Yap LB, Eng DT, Sivalingam L. et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Haemost. 2015 Epub ahead of print.
• 29 Maura G, Blotière PO, Bouillon K. et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015; 132: 1252-1260.
• 30 Avgil-Tsadok M, Jackevicius CA, Essebag V. et al Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2015; 115: 152-160.
• 31 Chan PH, Huang D, Hai JJ. et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm. 2015 Epub ahead of print.
• 32 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
• 33 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
• 34 Avgil-Tsadok M, Jackevicius CA, Rahme E. et al Sex differences in dabigatran use, safety, and effectiveness In a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outc 2015; 08: 593-599.
• 35 Nishtala PS, Gnjidic D, Jamieson HA. et al. 'Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. Int J Cardiol 2015; 203: 746-752.
• 36 Ansell J.. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012; 125: 165-170.
• 37 Lee S, Monz BU, Clemens A. et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross sectional analysis using the General Practice Research Database. Br Med J Open 2012; 02: 6 e001768.
• 38 Eikelboom JW, Hart RG.. Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight. Stroke 2015; 46: 5-6.
• 39 Dabigatran – Food and Drug Administration. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2014/022512s018lbl.pdf Accessed November 27, 2015.
• 40 Beasley BN, Unger EF, Temple R.. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011; 364: 1788-1790.
• 41 Uchino K, Hernandez AV.. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
• 42 Hohnloser SH, Oldgren J, Yang S. et al. Myocardial ischaemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125: 669-676.
• 43 Lip GY, Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-942.
• 44 Hart RG, Diner HC, Yang S. et al. Intracranial haemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
• 45 Ray WA.. Evaluating medication effects outside of clinical trials: new-user designs. Am J Med 2003; 158: 915-920.
• 46 Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.